Regular Article
Second-generation interferons for cancer: clinical targets

https://doi.org/10.1006/scbi.2000.0315Get rights and content

Abstract

IFNs were the first new therapeutic products resulting from recombinant DNA technology. IFNs were also the first human proteins effective in cancer treatment. There is however much to be discovered which will lead to new clinical applications. Areas which represent major research challenges for full understanding and application of the IFN system are: (i) the diversity of the IFN family; (ii) the role of induction; (iii) molecular mechanism of action; (iv) cellular modulatory effects; (v) advantages of combinations, and (vi) identification of new therapeutic indications. This review will emphasize the diversity of the IFN family and chemical modifications which will result in second-generation IFNs. Pre-clinical and clinical findings form the basis for new therapeutic directions in chronic myelogenous leukemia, lymphomas, myelomas, melanoma, urologic malignancies, primary brain tumors, and ovarian carcinoma.

References (202)

  • C MJ Selleri et al.

    Fas mediated modulation of ber/abl in chronic myelogenous leukemia results in differntial effects on poptosis

    Blood

    (1998)
  • M Schmidt et al.

    Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias

    Blood

    (1998)
  • I CM MacLennan et al.

    Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis

    Lancet

    (1992)
  • TJ McElwain et al.

    High-dose intravenous melphalan for plasma cell leukemia and myeloma

    Lancet

    (1983)
  • H Mellstedt et al.

    Interferon therapy in myelomatosis

    Lancet

    (1979)
  • A Osterborg et al.

    Natural interferon-alpha in combination with melphalan/prednisolone versus melphalan/prednisolone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden

    Blood

    (1993)
  • H Ludwig et al.

    Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicentre randomized trials and summary of other studies

    Ann Oncol

    (1995)
  • H Ludwig et al.

    Recombinant interferon alpha-2c versus polychemotherapy (VMCP) for treatment of multiple myeloma: A prospective randomized trial

    Eur J Cancer Clin Oncol

    (1986)
  • J Blalock et al.

    Purified human immune interferon has more potent anticellular activity than fibroblast or leukocyte interferon

    Cell Immunol

    (1980)
  • JL Harousseau et al.

    Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French registry on autologous transplantation in multiple myeloma

    Blood

    (1995)
  • JR Quesada et al.

    A collaborative phase I-II study of recombinant DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma and multiple myeloma

    Am J Med

    (1984)
  • R Ziesche et al.

    A long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis

    New Engl J Med

    (1999)
  • S Nagata et al.

    The structure of one of the eight or more distinct chromsomal genes for human interferon α

    Nature

    (1980)
  • DV Goeddel et al.

    The structure of eight distinct cloned human leukocyte interferon cDNAs

    Nature

    (1981)
  • PW Gray et al.

    Structure of the human immune interferon gene

    Nature

    (1982)
  • S Pestka

    The human interferon-alpha species and hydrid proteins

    Sem Oncol

    (1997)
  • MJ Hawkins et al.

    Comparison of the biologic effects of two recombinant human interferons alpha (rA and rD) in humans

    J Clin Oncol

    (1984)
  • BS Edwards et al.

    Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha interferons differing in antiviral activity

    Cancer Res

    (1984)
  • K Tong

    Research and development of recombinant interferon −α 1b

    J Interferon Cytokine Res

    (1997)
  • ON Ozes et al.

    A comparison of interferon-Con1 with natural recombinant interferons-alpha: antiviral, antiproliferative, and natural killer-inducing activities

    J Interferon Res

    (1992)
  • J Ortaldo et al.

    Effects of several species of human leukocyte interferon on cytotoxic activity of NK cells and monocytes

    Int J Cancer

    (1983)
  • JW Greiner et al.

    Differential effects of recombinant human leukocyte interferons on cell surface antigen expression

    Cancer Res

    (1986)
  • N Finter

    The classification and biological functions of the interferons. A review

    J hepatol

    (1986)
  • R Bukowski et al.

    Phase I Study of Polyethylene Glycol (PEG) Interferon Alpha-2b in Patients with Solid Tumors

    Proc Am Soc Clin Oncol

    (1999)
  • S McKenna et al.

    Enhancement of interferon-beta activity by complex formation with the soluble IFNAR-2 interferon receptor subunit

    J. Ifn Cytokine Res

    (1999)
  • FJ Ruzicka et al.

    Variation in the binding of 125I-labeled interferon-bser to cellular receptors during growth of human renal and bladder carcinoma cells in vitro

    Cancer Res

    (1987)
  • L Gardner et al.

    Initial interaction of human fibroblast and leukocyte interferons with FS-4 fibroblasts

    J Gen Virol

    (1982)
  • HE Broxmeyer et al.

    Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E) and granulocyte-macrophage (CFU-GM) progenitor cells

    J Immunol

    (1983)
  • A Hamburger et al.

    Cytotoxicity of human beta interferon for differentiating leukemic HL-60 cells

    Cancer Res

    (1985)
  • MN Gould et al.

    Radiosensitization of human bronchogenic carcinoma cells by interferon beta

    J Interferon Res

    (1984)
  • EC Borden et al.

    The comparative antiproliferative activity in vitro of natural interferons α and β for diploid and transformed human cells

    Cancer Res

    (1982)
  • M, G, Rosenblum, W, KA, Yung, P, J, Kelleher, F, Ruzicka, P, A, Steck, E, Borden, 1990, Growth inhibitory effects of...
  • JH Schiller et al.

    Synergistic antiproliferative effects of human recombinant α 54 or β ser with g interferon on human cell lines of various histogenesis

    Cancer Res

    (1986)
  • JH Schiller et al.

    Antiproliferative effects of interferons on human melanoma cells in the human tumor colony forming assay

    J Interferon Res

    (1986)
  • SD Der et al.

    Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays

    Proc Natl Acad Sci USA

    (1998)
  • C Chang et al.

    Evolution of a cytokine using DNA family shuffling

    Nature Biotechnol

    (1999)
  • R Hu et al.

    Divergence of binding, signaling, and biological responses to recombinant human hybrid

    IFN J Immunol

    (1999)
  • HM Kantarjian et al.

    Treatment of chronic myelogenous leukemia: curent status and investigational options

    Blood

    (1996)
  • M Taipaz et al.

    Recombinant IFN-alpha therapy of chromosome-negative myeloproliferative disorders with thrombocytosis

    Am J Med

    (1989)
  • J Butterfield et al.

    Interferon-alpha treatment of six patients with the idiopathic hyperepsinophilic syndrome

    Ann Intern Med

    (1994)
  • Cited by (75)

    • IFNs, ISGylation and cancer: Cui prodest?

      2012, Cytokine and Growth Factor Reviews
      Citation Excerpt :

      Secreted ISG15 can act as a cytokine, stimulating IFN type II production from CD3 + T cells [60] or as chemotactic factor for neutrophils [61]. IFNs treatment, alone or in combination with standard therapies has been used against many cancer types [62]. In certain cases type I IFNs are still in use whereas, in others, they have been replaced by new more efficient therapies.

    • Investigation on interferon alpha-inducible protein 6 (IFI6) gene as a candidate for meat and carcass quality in pig

      2011, Meat Science
      Citation Excerpt :

      IFI6 is not mapped yet in pig but the human IFI6 gene locates on HSAP1p35 which is homologous to a chromosomal region on the SSC6 where several QTL for meat quality traits (meat colour, water content, drip loss and pH, muscling and carcass length) have been mapped (Markljung et al., 2008; Taniguchi et al., 2010; Edwards et al., 2008). IFI6 is reported to have anti-apoptotic and immunomodulatory effects (Tahara et al., 2005; Urabe, 1994; Borden, Lindner, Dreicer, Hussein, & Peereboom, 2000; Schaar et al., 2005). Genes involved in apoptotic pathways were found to be down regulated in high drip loss animals (Ponsuksili et al., 2008).

    • Interleukin-7 treatment counteracts IFN-α therapy-induced lymphopenia and stimulates SIV-specific cytotoxic T lymphocyte responses in SIV-infected rhesus macaques

      2010, Blood
      Citation Excerpt :

      Over the last decade, immunotherapy has become increasingly important in the treatment of human pathologies. IFN-α–based therapy was the first and remains one of the most used treatments for viral infections, such as hepatitis C33 as well as an immunomodulating compound for stimulation of specific immunity in advanced cancers.34-37 Despite its efficacy, IFN-α treatment is always associated with significant side effects.

    • Influence of carbohydrates on the stability and structure of a hyperglycosylated human interferon alpha mutein

      2010, Biochimie
      Citation Excerpt :

      Later, other important functions of these cytokines were discovered, including potent antiproliferative and immunomodulatory effects [2]. Recombinant hIFN-α2 derived from genetically engineered Escherichia coli represents the cytokine exhibiting the longest record of use in clinical oncology, including treatment of hematological malignancies (hairy cell leukemia, chronic myeloid leukemia and some B- and T-cell lymphomas) and certain solid tumors (melanoma, renal carcinoma and Kaposi’s sarcoma) [3,4]. Also, because of its antiviral properties, rhIFN-α is the treatment of choice for patients with chronic hepatitis B and C virus infections [5,6].

    View all citing articles on Scopus
    View full text